Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

  • Kyowa Kirin expands the license agreement with one new ADC to a total of three ADC programs
  • Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC targetad technologies to develop up to three next generation conjugates
  • Decisions driven by highly competitive preclinical therapeutic index demonstrated by Kyowa Kirin’s lead program that was built by using Synaffix ADC technology
  • Triggers $5 million immediate payment to Synaffix and total potential payments for the first ADC program alone of up to $171m plus royalties on commercial sales

Read more